Cullinan Therapeutics to Present Phase 3 REZILIENT3 Interim Data on Zipalertinib Plus Chemotherapy at WCLC 2026, Host Investor Event

Cullinan Therapeutics (CGEM) announced positive interim results from its Phase 3 REZILIENT3 trial of Zipalertinib for EGFR exon 20 insertion mutation-positive NSCLC. The trial met its primary endpoint of progression-free survival. Data will be presented at IASLC 2026. CGEM had $356.0M in cash as of Q2 2026. The stock closed at $21.00, down 1.45%.

Cullinan Therapeutics (CGEM) shares rose 6.6% after positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant progression-free survival benefits. This positions zipalertinib as a potential first-line treatment for a specific subset of non-small cell lung cancer patients, supporting planned U.S. regulatory filings. Cullinan Therapeutics has no revenue but holds a high-risk pipeline with potential in oncology and autoimmune diseases.

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant improvement in progression-free survival for patients with EGFR exon 20 insertion mutations. The companies plan to submit full results for presentation at an upcoming medical conference and pursue U.S. regulatory approval. Zipalertinib would compete with Johnson & Johnson's amivantamab (Rybrevant) i

Taiho Oncology and Cullinan Therapeutics (CGEM) announced that Phase 3 REZILIENT3 trial data for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC will be presented at the 2026 IASLC World Conference. The trial met its primary endpoint of progression-free survival. Zipalertinib is an investigational EGFR inhibitor.

Cullinan Oncology (CGEM) shares rose about 6.4% pre-open after the company and partners reported REZILIENT3 Phase 3 results for zipalertinib plus platinum chemo in previously untreated EGFR exon 20 insertion NSCLC. The interim analysis met the primary endpoint with improved progression-free survival. The data supports U.S. first-line approval efforts, with up to $130M in milestones under the Cullinan-Taiho deal and a ~$334.5M cash balance.

Cullinan Therapeutics (Nasdaq: CGEM) reported Q2 2026 results and a corporate update. It said CLN-978 multi-dose data are planned for Q3 2026 (RA) and Q4 2026 (SLE), with Phase 2 expansions starting early 2027. CLN-049 Phase 2 in relapsed/refractory AML is planned for Q3 2026. Cash was $356.0M at June 30, 2026; net loss was $53.7M.